Tamar Thompson is Director at Avidity Biosciences, Inc. (RNA). They have made 1 open-market trade across 1 company since 2024, most recently 2026-02-27.
CIK 0001839248
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RNA | SELL | 2024-10-07 | 2024-10-09 | $44.98 | $1.3M | +4.8% | +4.8% | -30.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.